Evidence map›Paper›PMID 36884057›Full record

ArticleDiabetologia2023

Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cells.

René van Tienhoven, Maria J L Kracht, Arno R van der Slik, Sofia Thomaidou, Anouk H G Wolters, Ben N G Giepmans, Juan Pablo Romero Riojas, Michael S Nelson, Françoise Carlotti, Eelco J P de Koning and 3 more

Open access · hybridFull text read
In one paragraph

Article in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

René van TienhovenDepartment of Diabetes and Cancer Discovery Science, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID https://orcid.org/0000-0002-4035-7552
Maria J L KrachtDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
Arno R van der SlikDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-8920-0118
Sofia ThomaidouDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0003-1624-2138
Anouk H G WoltersDepartment of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Ben N G GiepmansDepartment of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-5105-5915
Juan Pablo Romero RiojasDepartment of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Michael S NelsonLight Microscopy Core, City of Hope National Medical Center, Duarte, CA, USA.
Françoise CarlottiDepartment of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0001-7929-8468
Eelco J P de KoningDepartment of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-1232-7022
Rob C HoebenDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0001-9443-8377
Arnaud ZaldumbideDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.ORCID https://orcid.org/0000-0001-6680-4456
Bart O RoepDepartment of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. b.o.roep@lumc.nl.ORCID https://orcid.org/0000-0002-3110-7391
Leiden University Medical Center · NLCity Of Hope National Medical Center · USUniversity Medical Center Groningen · NL

Funding

Integrated Islet Distribution Program (U24) - 2021U24DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Carmella Evans-Molina, Joyce Carol Niland · 2021 to 2026
$17.8M
Juvenile Diabetes Research Foundation 5-SRA-2018-557-Q-RNIDDK NIH HHS U24 DK098085ZonMw 91111.006
6 · The paper itself

Abstract

aims/hypothesisTranscriptome analyses revealed insulin-gene-derived transcripts in non-beta endocrine islet cells. We studied alternative splicing of human INS mRNA in pancreatic islets.

methodsAlternative splicing of insulin pre-mRNA was determined by PCR analysis performed on human islet RNA and single-cell RNA-seq analysis. Antisera were generated to detect insulin variants in human pancreatic tissue using immunohistochemistry, electron microscopy and single-cell western blot to confirm the expression of insulin variants. Cytotoxic T lymphocyte (CTL) activation was determined by MIP-1β release.

resultsWe identified an alternatively spliced INS product. This variant encodes the complete insulin signal peptide and B chain and an alternative C-terminus that largely overlaps with a previously identified defective ribosomal product of INS. Immunohistochemical analysis revealed that the translation product of this INS-derived splice transcript was detectable in somatostatin-producing delta cells but not in beta cells; this was confirmed by light and electron microscopy. Expression of this alternatively spliced INS product activated preproinsulin-specific CTLs in vitro. The exclusive presence of this alternatively spliced INS product in delta cells may be explained by its clearance from beta cells by insulin-degrading enzyme capturing its insulin B chain fragment and a lack of insulin-degrading enzyme expression in delta cells. CONCLUSIONS/

interpretationOur data demonstrate that delta cells can express an INS product derived from alternative splicing, containing both the diabetogenic insulin signal peptide and B chain, in their secretory granules. We propose that this alternative INS product may play a role in islet autoimmunity and pathology, as well as endocrine or paracrine function or islet development and endocrine destiny, and transdifferentiation between endocrine cells. INS promoter activity is not confined to beta cells and should be used with care when assigning beta cell identity and selectivity. DATA AVAILABILITY: The full EM dataset is available via www.nanotomy.org (for review: http://www.nanotomy.org/OA/Tienhoven2021SUB/6126-368/ ). Single-cell RNA-seq data was made available by Segerstolpe et al [13] and can be found at https://sandberglab.se/pancreas . The RNA and protein sequence of INS-splice was uploaded to GenBank (BankIt2546444 INS-splice OM489474).

Indexed as

InsulysinIslets of LangerhansHumansInsulinProtein Sorting SignalsRNASomatostatin-Secreting CellsInsulinInsulysinProtein Sorting SignalsRNAAlternative splicingAlternative translationBeta cellDefective ribosomal productDelta cellHuman islets of LangerhansInsulin-degrading enzymeInsulin geneType 1 diabetes

Identifiers

PMID36884057
PMCPMC10036285
OpenAlexW4323532373

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read2
measurements read29
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.